Agenus Inc. · NASDAQ:AGEN

Agenus — 2023 ASCO Gastrointestinal Cancers Symposium

10 slides from Agenus's conference presentation, Jan 21, 2023

  1. Slide 1: Results from a phase 1a/1b study of botensilimab plus balstilimab in MSS CRC

    Slide 1: Results from a phase 1a/1b study of botensilimab plus balstilimab in MSS CRC

    Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC) Authors: Anthony B. El-Khoueiry, MD1, Marwan G. Fakih, MD2, Michael S. Gordo

  2. Slide 2: Active in 'Cold' and IO Refractory Tumors

    Slide 2: Active in 'Cold' and IO Refractory Tumors

    2 Active in ‘Cold’ and IO Refractory Tumors botensilimab balstilimab Fc-enhanced CTLA-4 Inhibitor PD-1 Inhibitor Active in ‘cold’ and IO refractory tumors1,2 Safety and efficacy analogous to approved anti-PD-1 mAbs5,6 • >300 patients treated across 4 trials • >750 patients treated; 10 ongoing trials

  3. Slide 3: C-800 Study Design: MSS CRC Cohort

    Slide 3: C-800 Study Design: MSS CRC Cohort

    3 C-800 Study Design: MSS CRC Cohort NCT03860272: First-in-human trial of botensilimab ± balstilimab in patients with advanced cancer1 Key Eligibility for CRC BOT + BAL • Refractory Metastatic CRC • MSS by local assessment Fc-enhanced CTLA-4 PD-1 • Prior IO allowed 1 or 2 mg/kg Q6W 3 mg/kg Q2W • Tbi

  4. Slide 4: Patient Characteristics

    Slide 4: Patient Characteristics

    4 Patient Characteristics Characteristic Overall (N=70)* Characteristic Overall (N=70) Age, median (range) 57 (25-83) Prior immunotherapy, n (%) 22 (31) Sex, n (%) Botensilimab dose, n (%) Female 40 (57) 1 mg/kg Q6W + bal (PD-1) Q2W 17 (24) Male 30 (43) 2 mg/kg Q6W + bal (PD-1) Q2W 53 (76) ECOG PS a

  5. Slide 5: Deep Objective Responses

    Slide 5: Deep Objective Responses

    5 Deep Objective Responses 100 90 Change in Sum of Target Lesions (%) 80 70 60 50 40 30 20% Tumor Growth 20 ∞ 10 0 -10 -20 -30 -40 -50 30% Tumor Reduction -60 -70 § -80 -90 -100 Efficacy N=70 ORR*, % (95% CI) 23 (14-34) BOR, n (%) CR 1 (1) PR 15 (21) SD 37 (53) DCR (CR + PR + SD), % (95% CI) 76 (64-

  6. Slide 6: Durable Objective Responses

    Slide 6: Durable Objective Responses

    6 Durable Objective Responses Responder Characteristics (n=16) 100 Change in Sum of Target Lesions (%) 90 • 11/16 ongoing responses 80 • 3 with prior I-O (all refractory) 70 • 1/13 TMB >10 mut/Mb 60 • 1/8 PD-L1 positive (≥1%) 50 • 11 RAS mut 40 ∞ 20% Tumor Growth 30 20 10 0 -10 -20 -30 -40 30% Tumor

  7. Slide 7: Overall Survival

    Slide 7: Overall Survival

    7 Overall Survival Efficacy evaluable population, N=70 Overall No Active Liver Mets Active Liver Mets Median, OS (95% CI) NR (10.3-NR) NR (NR-NR) 9.4 (6.1-NR) 12-month, OS (95% CI) 63 (46-76) 81 (66-90) 40 (17-62) PRESENTED BY: Anthony B. El-Khoueiry, MD

  8. Slide 8: Safety Profile

    Slide 8: Safety Profile

    8 Safety Profile All TRAEs of Any Grade in ≥15% of All Patients ALL GRADE GRADE ALL GRADE GRADE n (%) n (%) GRADE 3 4 GRADE 3 4 ANY TRAE 64 (91) 28 (40) 2 (3) SKIN GASTROINTESTINAL Rash 19 (27) 0 0 IM diarrhea/colitis* 30 (43) 14 (20) 1 (1) Pruritus 12 (17) 0 0 Nausea 16 (23) 1 (1) 0 ENDOCRINE CONST

  9. Slide 9: Summary & Future Directions

    Slide 9: Summary & Future Directions

    9 Summary & Future Directions • Botensilimab is a CTLA-4 antibody with enhanced binding to activating Fc receptors enabling innate and adaptive immune activation • Durable objective responses in heavily pre-treated patients with MSS CRC • Manageable safety profile • Favorable overall survival: 12-mo

  10. Slide 10: Abbreviations and Acknowledgements

    Slide 10: Abbreviations and Acknowledgements

    10 Abbreviations Acknowledgements AE, adverse event IgG, immunoglobulin G ALT, alanine aminotransferase I-O, immunotherapy Agenus Inc. funded and is the sponsor of this APC, antigen presenting cell L, line AST, aspartate aminotransferase LOT, lines of therapy study. mAb, monoclonal antibody bal, bal

Source: Internet Archive copy of agenusbio.com

More decks from Agenus Inc.

All 34 Agenus decks